USFDA

Gland Pharma’s ₹6.29 Crore GST Dispute: What Investors Need to Know Introduction

10 Mar, 2026 13 mins read 80 views

Explore Gland Pharma’s ₹6.29 crore GST dispute from Telangana authorities over export reclassifications and credit notes for FY 2019-20. The company deems it unjustified and plans an appeal, assuring no major impact. Dive into company overview, market reactions, stock performance, and broader pharma sector implications as of March 9, 2026. Solid fundamentals persist amid short-term volatility.

Medical News

Cipla’s US Subsidiary Recalls Over 400 Cartons of Anti-Cancer Drug: What It Means for Patients and the Pharma Industry

10 Mar, 2026 15 mins read 119 views

Cipla USA has recalled over 400 cartons of Nilotinib, a generic anti-cancer drug for CML, due to minor manufacturing specs issues. This Class III recall poses no health risks but highlights quality controls in pharma. Explore implications for patients, Cipla’s stock, and the Indian generics industry in this detailed breakdown. Stay informed on USFDA updates for global drug safety.